Introduction ▼
A main result of the Sequenced Treatment Alternatives to Relieve Depression (STAR * D) trial [ 1 ] was that outpatients who initially received monotherapy with citalopram only showed remission in 28 % of the cases. Nevertheless, remission should be the aim of treatment [ 2 ] . Consequently failure to primary antidepressant treatment is quite common. However, strategies for second treatment steps, especially in comparison to each other, have rarely been investigated [ 3 ] . There are 4 frequently used pharmacological strategies for treatment of depression after initial antidepressant monotherapy showed no response: Lithium augmentation, switch of antidepressants, combination of antidepressants and rior to augmentation with placebo [ 10 ] . The OR for response to SGA vs. placebo was 1.69 and an NNT of 9 patients was calculated.
In conclusion, the evidence for diff erences regarding the effi cacy of diff erent pharmacological treatment strategies after failure to AD monotherapy varies and there are hardly any competitive investigations of these strategies [ 11 ] . Therefore further insight not only from RCTs but also from naturalistic trials of everyday clinical routine are warranted [ 12 ] . Particularly results gained from trials in clinical practice are required because the patient population of randomized controlled trials (RCTs) is often found to be biased [ 13 , 14 ] . However RCTs are the basis of advancing knowledge. Due to the lack of RCTs on this issue, the aim of this study was to fi nd diff erences in treatment response after failure of primary antidepressant monotherapy in a naturalistic design (lithium-augmentation, antidepressant-combination, switch of antidepressants, augmentation with SGA).
Methods

▼
The study was naturalistic in design and treatment was implemented according to the special needs of each patient. Treatment was not infl uenced due to the design of the study and analyses have been performed post-hoc. Over a period of 2 years all patients with a unipolar depression were included in the trial. The entry criteria included: (i) ICD-10 criteria for a major depressive episode or recurrent depression as the principal current diagnosis, (ii) aged 18 or older, (iii) informed consent from the patient, (iv) inpatient treatment duration ≥ 21 days [ 15 ] . After admission, the diagnosis of a depressive episode was done by the attending physicians within 3 days according to ICD-10 using the International Diagnostic Checklist [ 16 ] . Participants were excluded (i) if they had current severe alcohol or drug dependence (participants with mild to moderate alcohol or drug dependence were included), (ii) if they had a previous history of schizophrenia, schizoaff ective disorder, bipolar I disorder (a history of hypomania was permitted), (iii) if the depressive episode was attributable to organic illness and (iv) if they had such severe concentration defi cits to complete the questionnaires at admission (e. g.), had language diffi culties or did not complete the questionnaires at discharge ( • ▶ Fig. 1 ). The study has been conducted in accordance with the current version of the Declaration of Helsinki and was approved by the local Ethics Committee. Patients were treated under consideration of the German S3 guideline for treatment of depression [ 17 ] . All psychiatric drugs, the medication class, the dosage and the treatment duration were recorded systematically. In addition, the duration and type of other treatments like psychotherapy, occupational therapy, physical therapy or art therapy were recorded.
Assignment
Only patients with an initial antidepressant monotherapy with a duration of 21-35 days (phase I) were analyzed followed by an evaluation of the response to treatment by the attending clinicians. In 135 cases, patients showed an indication for change of treatment according to the clinical judgement (no defi ned measurement). 98 patients met criteria for assignment to one of the 4 treatment groups (phase II): 1) Lithium-augmentation (Li-Augm), 2) switch of antidepressants (AD-Switch), 3) combination of antidepressants (AD-Comb), 4) augmentation with SGA (SGA-Augm). Criteria for enrolment into analysis were: patients had to have an adequate antidepressant monotherapeutic treatment in phase I according to duration (21-35 days) and dosage ( • ▶ Table 1 , recommendations for doses of antidepressants, doses used in this study). Only experienced clinicians assigned the patients to the appropriate treatment group according to the patients' medical/psychiatric needs. Change of medication was not caused by side eff ects of the phase I treatment. There were no other psychotropic drugs in phases I and II other than the medication of the treatment groups. Treatment in phase II was adequate in doses and duration. Patients who received a third treatment step due to failure in phase II were not included in the analysis. To assess the severity of depressive symptoms, clinician-rated and self-rating instruments were used at admission and at discharge (t1 and t2). Treatment groups were as heterogeneous as they normally appear in clinical practice.
Diagnostic methods
The severity of depressive symptoms was measured using clinician-rated and self-rated assessment procedure. The Hamilton rating scale for depression (HRSD 17 ) was used to assess the severity of depressive symptoms [ 15 ] and was the primary outcome criterion. It was performed by trained psychologists who were blinded regarding the treatment arm. Secondary measures included the Beck depression inventory [ 18 ] and the Brief symptom inventory (BSI) to assess the patients' depressive and general psychological symptoms as means of self-assessment [ 19 ] . The attending physicians rated the patient's global level of functioning using the Global assessment of functioning scale (GAF) [ 20 ] as well as the global severity of the psychiatric disorder using the Clinical global impression scale (CGI) [ 21 ] . The assessment of personality disorders was performed using the structured clinical interview for DSM-IV personality disorders (SKID II) and was conducted by trained and experienced clinical psychologists 3 weeks after admission [ 22 ] . All raters were given training and supervision to perform clinician-rated assessment procedures (HRSD, CGI, GAF, SKID II).
Statistics
To analyze if patients in the 4 treatment groups were comparable, analysis of variance followed by post-hoc tests (parametric data) or Kruskall-Wallis test followed by Mann-Whitney U-test (non-parametric data) for important psychometric characteristics were performed. Signifi cant diff erences were added as covariates in the following analyses. The primary analysis for examining changes over time was a 2 × 2 ANCOVA with the 2 factors "treatment" and "time", controlling for pre-treatment scores (repeated-measure ANCOVA). Afterwards, post-hoc analyses for diff erences between treatment groups were performed. All signifi cance tests were performed at a 2-tailed alpha level of 0.05, incorporating an LSD procedure for multiple comparisons.
For all tests, eff ect sizes (ES) for independent random samples were calculated using Cohen's d statistic and the eff ect sizes for repeated measures [ 23 ] . At the end of treatment, the remission rates under the 4 treatment conditions were compared using 2-sided Pearson's χ 2 tests (remission: HRSD < 8) [ 24 ] . The statistical analyses were carried out using SPSS 17.
Results
▼
A total of 283 patients were screened. 277 patients met the inclusion criteria and 224 patients were enrolled in the study. 135 patients (47.7 %) showed no response after initial antidepressant monotherapy and were therefore assigned to one of the 4 treatment groups. Another 37 patients (13.1 %) were excluded due to polypharmacy, diff erent treatment strategies or treatment steps after phase II. Therefore 98 patients (34.6 %) were included in the study protocol. • ▶ Fig. 1 shows the study chart including reasons for drop out. • ▶ Table 2 displays baseline demographic and illness characteristics for the entire sample. A severe depressive episode was the principal diagnosis in 43.7 % of patients and a recurring severe depressive episode was diagnosed in 27.6 % of all cases using ICD-10. There were no significant treatment group diff erences in baseline demographic or illness characteristics and comorbidities. The average HRSD score on admission was 28.2 ( SD = 11.1) characterising a patient group with rather severe depressive symptoms. Antidepressant medication in phase I was similar in the treatment groups ( • ▶ Table 2 ). Change of treatment was performed after an average of 27.3 days (SD: 5.7) without diff erences between the treatment groups (F = 1.27; p = 0.28). Characteristics of treatment in phase II including medication classes are displayed in • ▶ Table 3 and were also checked for duration and dosage. Again there was no diff erence between the treatment groups in terms of duration in phase II (F = 1.02, p = 0.47 
Treatment eff ects
Analysis of variance for repeated measures revealed a signifi cant improvement and large eff ect sizes for all patients from baseline to discharge in all inventories (HRSD: F = 648, p = < 0.001; BDI: F = 194.7, p = < 0.001; BSI-GSI, F = 167.59, p = < 0.0). According to [ 23 ] eff ect sizes d for repeated measurements indicate a substantial reduction (d > 0.80) of depressive symptoms (ES HRSD d = 3.2, ES BDI = 1.9) and general psychological distress (ES BSI-GSI = 1.6) during treatment. The interaction eff ect "time by treatment condition" indicated a signifi cant diff erence in the amount of reduction of the depression severity measured using the HRSD between the 4 treatment groups (HRSD: F = 2.84, p = 0.04; BDI: F = 3.68, p = 0.01; • ▶ Table 4 ). The subsequent post-hoc analyses ( • ▶ Table 5 ) revealed a signifi cantly higher improvement for Li-Augm over AD-Switch (mean diff erence [MD]: 2.72, p = 0.02) and for Li-Augm over AD-Comb (MD = 3.45, p = 0.02) in the HRSD. Likewise SGA-Augm showed a signifi cant higher improvement compared to AD-Switch (MD = 2.34, p = 0.04) and AD-Comb. (MD = 3.07, p = 0.03). The BDI score showed similar results: Patients in the Li-Augm rated a higher improvement of their depressive symptoms compared to AD-Switch (MD = 3.32, p = 0.04) and AD-Comb. (MD = 6.32, p < 0.01). Patients augmented with SGA also showed a greater reduction in the BDI than patients with AD-Comb (MD = 4.03, p = 0.04), but not compared to AD-Switch (MD = 1.03, p = 0.56). There were no signifi cant diff erences between Li-Augm and SGA-Augm in the HRSD or the BDI. Regarding the amount of reduction in general psychological symptoms (BSI-GSI) signifi cant diff erences between the treatment groups could be found (BSI-GSI, F = 2.87; p = 0.04). Patients with Li-Augm and SGA-Augm had higher amount of reduction than patients with AD-Comb (Li-Augm: MD = 0.44, p < 0.01, SGA-Augm: MD = 0.31, p = 0.03).
Remission rates
Comparing the remission rates between the 4 treatment conditions, patients with Li-Augm showed higher remission rates (89.3 %) in the HRSD with a statistical trend (p < 0.1) compared to AD-Switch (40.7 %; χ 2 = 3.07; p = 0.08) but not to AD-Comb (AD-Comb: 42.9 %; χ 2 = 1.75, p = 0.19). The SGA-Augm-group also had higher remission rates (86.2 %) compared to AD-Switch (χ 2 = 2.82, Li-Augm, lithium augmentation; AD-Switch, antidepressant switch; AD-Comb, antidepressant combination, SGA-Augm, augmentation with second generation antipsychotics; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants; SNRI, serotonin-norepinephrine reuptake inhibitors; AD, antidepressants; SD, standard deviation; n, numbers; χ 2 chi square % HAMD BDI p = 0.09) but not to AD-Comb (χ 2 = 1.59, p = 0.21). All remission rates are displayed in • ▶ Fig. 2 .
Global functioning and clinical global impression
Overall functioning improved considerably from baseline to discharge (GAF: F = 250.1, p < 0.001, ES pre-post : d = 2.3) for all patients. Also there was a signifi cant reduction in general severity of disorder from intake to discharge (CGI: F = 524.2, p < 0.001, ES pre-post : d = 3.4). The interaction eff ect "time by treatment con-dition" indicated signifi cant diff erences between treatment conditions regarding the amount of reduction from baseline to discharge (GAF: F = 5.21, p = 0.002; CGI: F = 4.28, p = 0.007; • ▶ Table 3 ). Posthoc analyses ( • ▶ Table 4 ) again revealed a higher gain of functioning (GAF) for the Li-Augm compared to AD-Comb (MD = 0.78, p < 0.01). Patients in the SGA-Augm group also had a higher improvement compared to AD-Switch and AD-Comb (AD-Comb: MD = 0.90, p < 0.01 [trend]; AD-Switch: MD = 0.37, p = 0.08). Improvement in GAF did not diff er between Li-Augm and SGA-Augm. Both groups Li-Augm and SGA-Augm had signifi cantly higher improvement in the CGI compared to AD-Comb (Li-Augm: MD = 0.58, p < 0.01; SGA-Augm: MD = 0.66, p < 0.01) and to AD-Switch (Li-Augm: MD = 0.29, p = 0.05; SGA-Augm: MD = 0.37, p = 0.01).
Safety measurements and compliance
Adverse events reported by the patients were recorded. Somatic complaints were assessed and recorded. There was no relevant diff erence between the groups in the percentage of patients in the safety set who reported at least one emergent adverse event on treatment (51 %). There were no deaths during the study and no suicide attempts. The most frequently aff ected systemic organ classes were gastrointestinal disorders (18.4 %) and nervous system disorders (20.5 %). The most frequent emergent adverse events were headache, nausea, and somnolence.
Discussion
▼
The present study investigated diff erences in treatment outcome between 4 diff erent pharmacological treatment strategies after failure of the primary antidepressant monotherapy. In this naturalistic design, 60 % of the depressive patients failed to show remission after primary treatment. This number is lower compared to the the STAR*D trial, where 72 % of patients failed to reach remission after citalopram monotherapy in treatment step one (1) . Contrary to the STAR*D study, which only included outpatients, the present study only included inpatients. Nevertheless, overall results are comparable to those of other "eff ectiveness" studies investigating the quality of inpatient treatment of depression. In a multicenter trial of the German Research Network on Depression investigating suicidality in 1 014 patients, response rates of 68.9 % and remission rates of 51.9 % in the HRSD could be achieved [ 25 ] . The second treatment step showed diff erent response and remission rates depending on the treatment group. Generally, all patients showed relatively high response rates after treatment in step 2 (remission rate in HRDS: 30 %). Compared to the second treatment step in the STAR*D study, (remission rate 25 %), remission rates of the present study were to some extent higher. Possible explanations are the multiprofessional treatment approach including high additional eff ords such as psychotherapy, occupational therapy or physical therapy in the current study. However, comparing only the treatment step 2 of STAR*D (AD-Switch or -combination) with the corresponding treatment groups of the present study, remission rates do approach comparable numbers (remission rate [HRSD]: AD-comb: 42.9 %; AD-Switch: 40.7 %). Focussing on the diff erences between the 4 treatment groups in step 2, it is notable that patients who received a non-antidepressant as the second step (lithium or SGAs) had lower depressive symptoms than subjects who received continued treatment with antidepressants (switch or combination). The good outcome of the lithium augmented patients is in line with empirical evidence for this treatment approach [ 9 ] . Also augmentation with SGA showed lower scores of depressive symptoms compared to AD-Switch and AD-Comb. Response rates were relatively high compared to previous studies. Bauer et al. (2009) found response rates of 55 % for augmentation after nonresponse to antidepressant monotherapy [ 26 ] . For antidepressant augmentation with aripiprazole [ 27 ] and olanzapine [ 28 ] , response rates were 33.7 % and 25 %, respectively. In the metaanalysis of Nelson and Papakostas (2009) overall effi cacy of augmentation with SGA in treatment-resistant depression has been proven and is in line with the data of our naturalistic study. There has been a lot of research regarding possible antidepressant eff ects of SGA focusing on the multiple eff ects of those substances on diff erent neurotransmitters and their second messengers. The mediocre outcome of switching the antidepressant in this naturalistic study is in line with recent fi ndings of RCTs showing that there is no evidence supporting this strategy [ 5 ] . Instead there are data suggesting inferiority of continuing the hitherto not eff ective antidepressant [ 8 ] . Also AD-Comb was part of the second step of STAR*D: The combination included citalopram and bupropion with remission rates of 30 %. But RCTs only found superiority for reuptake-inhibitors in combination with alpha-2-antagonists compared to placebo [ 29 , 30 ] .
In summary, although AD-Switch and AD-Comb show moderate remission rates in the present study, they might produce lower improvement and lower remission rates compared to Li-Augm or augmentation with SGAs. As noticed before, a possible reason for this is the relatively similar way of functioning of ADs, increasing the levels of serotonin and/or norepinephrine in the synaptic cleft (with few exceptions). However, antidepressant agents diff er in the mode of action and specifi city of increasing neurotransmitters. A possible conclusion could be that patients who do not respond to substances with this mode of functioning do have a higher benefi t with medications of a diff erent mode of action. Possible explanations of superiority of Li-Augm compared to AD-Switch or AD-Comb include the diversity of pharmacological functioning: Lithium infl uences the neurotransmittersystem on the level of second messengers and gene-regulation [ 31 ] . Previous research has also focused on possible antidepressant eff ects of SGAs particularly on the multiple eff ects of those substances on diff erent neurotransmitters and their second messengers. For example, aripiprazole has a partial dopamine receptor agonism and quetiapine an additional norepiphreninreuptake-inhibition, which both are relevant in other antidepressant substances [ 32 , 33 ] . In contrast, AD just have impact on extracellular receptors with a minor infl uence on multiple neurotransmitters.
Conclusion
▼
This naturalistic study confi rmed that lithium augmentation as well as augmentation with SGA each showed better outcome than AD-Switch and AD-Comb. Possible reasons are the diversity of functioning compared to the homologous eff ects in the group of antidepressants. However, there is nevertheless the risk of additional side eff ects of these 2 medication groups. Lithium treatment should be conducted in line with the established safety procedures. SGA and their eff ect on metabolic function as well as tardive dyskinesias are present and are criticized as underestimated [ 34 ] . Especially for the group of SGA the costs of medication should be taken into account. Therefore diff erent treatment options, for example, additional psychotherapy or ECT [ 35 , 36 ] should be considered. In conclusion, this study indicates diff erences between treatment strategies after failure of primary treatment in unipolar depression. RCTs are absolutely necessary to confi rm these fi ndings. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. Limitations ▼ Despite the statistical control for infl uencing variables (medication, psychosocial factors, additional therapies, duration of treatment), the naturalistic design (no randomization to treatment groups) of the study can be regarded as a shortcoming and could infl uence the results. The lack of a defi ned measurement of non-response after phase I is also a major limitation. Therefore it is possible that not all patients really did show nonresponse to primary treatment. Furthermore the heterogeneous treatment in phase I could have had an infl uence on treatment outcome. Phase II was heterogeneous in treatment as well (different SGAs, diff erent switch strategies, diff erent AD combinations). Pharmacological diff erences of ADs were not fully considered in the question of the AD-comb or AD-switch. Therefore inferiority of those strategies could have been infl uenced by irrational switching or combination strategies. However, there is low evidence of effi cacy of switching [ 5 ] or combination strategies [ 7 ] at all , and especially with regard to certain combinations or switching sequences . Another relevant aspect is that measurement at t2 was at discharge and not on a predefi ned time point. Although there were no signifi cant diff erences of treatment duration between the 4 treatment arms, this could have had an infl uence on the results. In general it should be mentioned that there was no placebo group. Both groups with augmentation strategies received prolonged treatment with one antidepressant. It cannot be excluded that patients in these groups had lower depressive symptoms mainly because of prolonged exposure to the antidepressants. In conclusion, there is the possibility that treatment groups are not comparable. In further research there also should be an arm that continues the last treatment to observe eff ects of longer treatment and of spontaneous response. Therefore, the results in this naturalistic study indicate diff erences between these treatment strategies but all signifi cant associations must be viewed with caution. Nevertheless, the present study is the fi rst study that compared diff erent pharmacological treatment options after failure of primary antidepressant monotherapy with each other. Despite the methodological limitations mentioned, this study under naturalistic condition is an important completion to fi ndings from randomised and controlled studies [ 37 , 38 ] . Either way, controlled studies, e. g., with randomization are required to confi rm the fi ndings from this study.
